会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Method of treating interstitial cytitis with recombinant heparin-binding epidermal growth factor-like growth factor (HB-EGF)
    • 用重组肝素结合表皮生长因子样生长因子(HB-EGF)治疗间质性膀胱炎的方法
    • US06232289B1
    • 2001-05-15
    • US09293037
    • 1999-04-16
    • Susan KeayJohn WarrenMichael Hise
    • Susan KeayJohn WarrenMichael Hise
    • C07K1400
    • A61K38/1808
    • Interstitial cystitis (IC) is a chronic bladder disease for which the exact etiology is unknown and for which there is no reliably effective treatment. However, it is known that the bladder epithelium is often abnormal in IC. We discovered that human bladder epithelial cells from both normal controls and IC patients are inhibited from proliferating by an anti-proliferative factor (APF) present in IC urine specimens. Inhibited proliferation may cause epithelial abnormalities characteristic of IC such as ulcerations and multiple tears in the bladder epithelium. We further discovered that 1) levels of heparin binding-epidermal growth factor-like growth factor (HB-EGF), a factor known be important for epithelial cell proliferation and wound healing in other tissues, are abnormally low in the urine of patients suffering from IC as compared to asymptomatic controls or patients with acute bacterial cystitis; 2) the APF found in IC urine specimens inhibits HB-EGF production by bladder epithelial cells; and 3) that the administration of rHB-EGF blocks the effects of APF on bladder epithelial cells from either IC patients or controls. The invention herein is directed to the administration of HB-EGF, or a functional derivative or agonist thereof, to bladder epithelial cells to inhibit the effects of APF on bladder cell proliferation, thereby reducing or eliminating the chronic damage to the bladder epithelium. HB-EGF or a functional derivative may be used as a therapy for patients suffering from IC or other diseases characterized by inhibited epithelial cell proliferation.
    • 间质性膀胱炎(IC)是一种慢性膀胱疾病,其确切的病因是未知的,并且没有可靠的有效治疗。 然而,已知膀胱上皮在IC中通常是异常的。 我们发现来自正常对照组和IC患者的人膀胱上皮细胞被IC尿液标本中存在的抗增殖因子(APF)抑制增殖。 抑制性增殖可能导致IC的特征性上皮异常,如膀胱上皮中的溃疡和多发性泪液。 我们进一步发现,1)肝素结合表皮生长因子样生长因子(HB-EGF)水平是已知对其他组织中的上皮细胞增殖和伤口愈合很重要的因素,在患有尿液的患者的尿液中异常低 IC与无症状对照或急性细菌性膀胱炎患者相比; 2)IC尿液标本中发现的APF可抑制膀胱上皮细胞产生HB-EGF; 和3)rHB-EGF的给药阻断APF对来自IC患者或对照的膀胱上皮细胞的影响。 本发明涉及向膀胱上皮细胞施用HB-EGF或其功能性衍生物或激动剂,以抑制APF对膀胱细胞增殖的影响,从而减少或消除膀胱上皮细胞的慢性损伤。 HB-EGF或功能衍生物可用作患有IC或其它以抑制性上皮细胞增殖为特征的疾病的患者的治疗。